You are here

  • Home
  • Archive
  • Volume 73, Issue Suppl 2
  • AB0423 Impact of Anti-IL-6 Monoclonal Antibody, Clazakizumab, on Patient-Reported Outcomes in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate in A Phase Iib Study

Alerts

Article menu
Download PDFPDF
EULAR 2014: Scientific Abstracts
Abstracts accepted for publication. Rheumatoid arthritis - other biologic treatment
AB0423 Impact of Anti-IL-6 Monoclonal Antibody, Clazakizumab, on Patient-Reported Outcomes in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate in A Phase Iib Study
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address